Overview
Valius Sciences develops precision oncology diagnostics that build detailed molecular profiles of tumors across DNA, RNA, and proteins to guide treatment choices. Its test combines multi-omic data and extensive gene expression analysis to identify actionable targets and cancer drivers that may be missed by standard tests. Rather than static PDFs, it offers a partnership model with an AI-queryable platform that stores all patient data and enables ongoing analysis and collaboration with Valius's scientific team. The goal is to help patients and clinicians prioritize effective therapies and plan for recurrence or progression through continuous, data-driven insights.
Work here?Claim your company
Simplify's Take
What believers are saying
- Valius raised $13.5 million on April 9, 2026, from 8VC and Basis Set.
- The company now advertises active support for trial matching and single-patient INDs.
- Valius says it is expanding clinical single-cell gene-expression analysis and its scientist team.
What critics are saying
- Direct-pay pricing of $50,000-$90,000 kills routine adoption without reimbursement.
- Tempus, Guardant Health, and Foundation Medicine already own oncologist workflows.
- If payers or tumor boards reject maximalist reports, Valius loses referrals quickly.
What makes Valius Sciences unique
- Valius sells DNA-RNA-protein tumor profiling, not single-layer sequencing.
- It offers direct-pay, patient-facing interpretation plus ongoing scientific collaboration.
- Its platform supports clinical trial matching, single-patient INDs, and recurrence monitoring.
Help us improve and share your feedback! Did you find this helpful?